NF-κB as a target for pancreatic cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL.2, 2012, Pages

  Carbone, Carmine ^a   Melisi, Davide ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

NF B; pancreatic cancer; TAK1; targeted therapy

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

ARTICLE; CANCER RESISTANCE; CYTOSOL; DRUG TARGETING; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PANCREAS CANCER; TUMOR CELL;

ANIMALS; HUMANS; MAP KINASE KINASE KINASES; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84858956777     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.645806     Document Type: Article

References (73)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;5:277-300
2. Wolff RA. Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy. Cancer J 2007;13:175-84
3. Vaccaro V, Melisi D, Bria E, et al. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets 2011;10:1183-96
4. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011;8:715-23
5. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;49:6938-47
6. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;3:241-6 (Pubitemid 32157954)
7. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;4:301-10 (Pubitemid 37328783)
8. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;2:135-42 (Pubitemid 32096826)
9. Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappaB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;1:119-27 The first report, to our knowledge, demonstrating constitutive activation of RelA in a nonlymphoid human cancer such as pancreatic cancer. (Pubitemid 29045184)
10. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009;4:a000034
11. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-224
12. Huxford T, Huang DB, Malek S, Ghosh G. The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 1998;6:759-70 (Pubitemid 29014456)
13. Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998;6:749-58
14. Malek S, Chen Y, Huxford T, Ghosh G. IkappaBbeta, but not IkappaBalpha, functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NF-kappaB nuclear localization sequences in resting cells. J Biol Chem 2001;48:45225-35
15. Huang TT, Kudo N, Yoshida M, Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci USA 2000;3:1014-19 (Pubitemid 30080804)
16. Johnson C, Van Antwerp D, Hope TJ. An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IkappaBalpha. Embo J 1999;23:6682-93
17. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109:S81-96
18. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002;1:20-6 (Pubitemid 34065613)
19. He G, Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011;1:159-68
20. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;4:297-309 (Pubitemid 40488635)
21. Kearns JD, Basak S, Werner SL, et al. IkappaBepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression. J Cell Biol 2006;5:659-64 (Pubitemid 46165574)
22. Lee SH, Hannink M. Characterization of the nuclear import and export functions of IkappaBepsilon. J Biol Chem 2002;26:23358-66 (Pubitemid 34952166)
23. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 2011;1:71-85
24. Razani B, Zarnegar B, Ytterberg AJ, et al. Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation. Sci Signal 2010;123:ra41
25. Joyce D, Albanese C, Steer J, et al. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001;1:73-90 (Pubitemid 32294588)
26. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;7319:1114-17
27. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;5897:1801-6
28. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008;4:306-16
29. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003;1:346-54 (Pubitemid 36109751)
30. Fujioka S, Sclabas GM, Schmidt C, et al. Inhibition of constitutive NF-kappaB activity by IkappaBalpha M suppresses tumorigenesis. Oncogene 2003;9:1365-70 (Pubitemid 36384598)
31. Vimalachandran D, Greenhalf W, Thompson C, et al. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 2005;8:3218-25 (Pubitemid 40524604)
32. Weichert W, Boehm M, Gekeler V, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007;4:523-30 (Pubitemid 47258447)
33. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;6:883-99
34. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;6:2095-147 (Pubitemid 26086851)
35. Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006;3:387-408 (Pubitemid 44922357)
36. Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation inpancreatic cancer cells. J Biol Chem 2004;16:16452-62 A demonstration that an autocrine stimulation of IL-1α accounts for the constitutive activation of NF-κB in pancreatic cancer.
37. Melisi D, Niu J, Chang Z, et al. Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res 2009;5:624-33
38. Carbone C, Moccia T, Zhu C, et al. Anti-VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res 2011;17:5822-32
39. Arlt A, Vorndamm J, Muerkoster S, et al. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002;3:910-16 (Pubitemid 34126972)
40. Muerkoster S, Wegehenkel K, Arlt A, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004;4:1331-7 (Pubitemid 38235601)
41. Kiefel H, Bondong S, Erbe-Hoffmann N, et al. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression. Oncogene 2010;34:4766-78
42. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;7:517-31 (Pubitemid 351881844)
43. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;4:549-54
44. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;7269:108-12 This paper describes the identification of the non-canonical IκB kinase TBK1 among the top potential KRAS synthetic lethal partner genes.
45. Shen RR, Hahn WC. Emerging roles for the non-canonical IKKs in cancer. Oncogene 2011;6:631-41
46. Clement JF, Meloche S, Servant MJ. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res 2008;9:889-99
47. Bonnard M, Mirtsos C, Suzuki S, et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. Embo J 2000;18:4976-85
48. Korherr C, Gille H, Schafer R, et al. Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci USA 2006;11:4240-5
49. Melisi D, Chiao PJ. NF-kappaB as a target for cancer therapy. Expert Opin Ther Targets 2007;2:133-44
50. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010;10-12:775-87
51. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;1:11-17 (Pubitemid 32802698)
52. Marten A, Zeiss N, Serba S, et al. Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. Mol Cancer Ther 2008;11:3624-31
53. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;1:59-70 (Pubitemid 39193679)
54. Alberts SR, Foster NR, Morton RF, et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 2005;10:1654-61 (Pubitemid 41510140)
55. M.D. Anderson Cancer Center. Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer. ClinicalTrials.gov NCT00416793 Available from: http://clinicaltrials.gov/ct2/show/NCT00416793?term= NCT00416793&rank=1
56. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008;4:787-809
57. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491-9
58. Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995;5244:2008-11 The original identification of the TGF-β-activated kinase-1 (TAK1).
59. Adhikari A, Xu M, Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007;22:3214-26 (Pubitemid 46763016)
60. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, et al. The kinase TAK1 can activate the NIK-IkappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999;6724:252-6
61. Thiefes A, Wolter S, Mushinski JF, et al. Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor target genes. J Biol Chem 2005;30:27728-41 (Pubitemid 41076887)
62. Omori E, Matsumoto K, Sanjo H, et al. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J Biol Chem 2006;28:19610-17 (Pubitemid 44035464)
63. Sato S, Sanjo H, Takeda K, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005;11:1087-95 (Pubitemid 41541786)
64. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007;7:2727-35 (Pubitemid 46482064)
65. Choo MK, Kawasaki N, Singhirunnusorn P, et al. Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol Cancer Ther 2006;12:2970-6
66. Melisi D, Xia Q, Paradiso G, et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 2011;103:1190-204
67. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev 2009;7:412-22
68. Deer EL, Gonzalez-Hernandez J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010;4:425-35
69. Gysin S, Rickert P, Kastury K, McMahon M. Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines. Genes Chromosomes Cancer 2005;1:37-51 (Pubitemid 41060195)
70. Pan X, Arumugam T, Yamamoto T, et al. Nuclear factor-kappaB p65/ relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 2008;24:8143-51
71. Le X, Shi Q, Wang B, et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2000;11:935-46
72. Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 2000;17:9624-9 (Pubitemid 30650826)
73. Shiah HS, Gao W, Baker DC, Cheng YC. Inhibition of cell growth and nuclear factor-kappaB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Mol Cancer Ther 2006;10:2484-93 (Pubitemid 44650912)